Cells From Bone Marrow Calm Damaging Immune Response
By Brandon Levy
Tuesday, April 28, 2020
In patients with the inflammatory disease sarcoidosis, the body’s own immune cells rampage around the body like The Incredible Hulk set loose in a city, attacking both harmful pathogens and our own tissues. However, just like the Black Widow can calm The Hulk down and return him to human form in the Avengers films, cells isolated from our bone marrow may be able to change certain immune cells from a damaging state to a benign one, according to new IRP research.
Treatment Regimen Allows Genetically Mismatched Skin Grafts in Mice
By Brandon Levy
Tuesday, June 25, 2019
Thousands of patients who need an organ transplant die each year before a donor can be found. A new IRP study has identified a safer way to prevent a transplant recipient’s body from attacking a genetically dissimilar donor organ, which could dramatically expand the pool of potential organ donors.
New Technique Overcomes Major Obstacle to Stem-Cell-Based Treatments
By Brandon Levy
Tuesday, May 14, 2019
Your brain cells need plenty of oxygen and nutrients to survive — that is, unless you’re a hibernating ground squirrel. By tapping into the cellular process that keeps these animals’ brains healthy during the long winter months, IRP scientists have discovered a way to increase the survival of neuron-producing stem cells implanted into the brain after a stroke, a development that could one day dramatically improve stroke treatment.
Discovery Could Lead to New Approaches for Boosting Blood Cell Counts
By Brandon Levy
Tuesday, March 19, 2019
Much of human biology is a black box — scientists know the key players and the end results, but not how those outcomes come about. Consequently, it remains a mystery why some medications help patients. A new IRP study has cracked open the black box to reveal how high levels of an inflammatory molecule inhibit blood cell production in some individuals and why a particular medicine helps reverse this life-threatening condition.
By Brandon Levy
Tuesday, October 30, 2018
Every good gardener knows the importance of fertilizing the soil before planting seeds, and evidence is accumulating that a similar concept applies to the human body when it comes to experimental stem cell therapies. A new IRP study has uncovered how a medical technology called pulsed-focused ultrasound boosts the healing potency of a particular stem cell treatment.
By Michael Gottesman
Thursday, June 22, 2017
Michael A. Beaven died unexpectedly on Saturday, April 8, 2017, at age 80. Mike was an expert in mast cell biology and beloved friend and colleague of many. He had worked at the NIH since 1962.
In the past seven years during his formal “retirement,” Mike remained incredibly productive, coauthoring more than 20 primary publications as well as a number of reviews; and he continued to perform experimental work as well as being the “go to” scholar in a range of areas.
By Michael Gottesman
Tuesday, April 4, 2017
Last month I moderated our annual retreat with the NIH Scientific Directors, those individuals tasked with leading their Institute or Center (IC)-based intramural research program. We were joined by many of the IC Clinical Directors. And this year we decided to do something a little different: listen to a series of talks about exciting, new IRP research.
By Jeanelle Spencer
Wednesday, January 7, 2015
For the junior scientist, the poster session is a rite of passage, an opportunity to think about the big picture, and an exercise in communicating your work to a broad audience.
By Jeanelle Spencer
Monday, December 1, 2014
Ever since studying transposons (mobile genetic elements) in graduate school, I’ve been fascinated by DNA and the many natural ways DNA moves and recombines within genomes. Transposons are responsible for multidrug resistance in bacteria, and the major players in V(D)J recombination in humans were derived from transposons. Now, as a postdoctoral fellow in the National Cancer Institute of the NIH, I conduct research focused on gene therapy strategies for hematologic malignancies and immunodeficiencies, because I am interested in the clinical application of basic biology.
By Francis Collins, Michael Gottesman
Monday, November 17, 2014
You only have to glance at the mainstream news – never mind the scientific press – to know that the 21st century is biomedical science’s most exciting time ever.
